Literature DB >> 18801115

A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Jennifer L Martelle1, Michael A Nader.   

Abstract

Eticlopride is a substituted benzamide analog with high affinity and selectivity for dopamine (DA) D2-like receptors that was initially developed as a potential antipsychotic agent. A great deal of research has utilized this drug to better understand central DA receptor function, the role of D2-like receptors in behavior, and the influence of blockade of these receptors on several preclinical animal models. This review highlights research utilizing this drug and compares it to typical and atypical antipsychotics used clinically. First, we describe structure-activity relationships as it relates to binding at DA receptors and the consequences on behavior. This is followed by a discussion of several imaging strategies including the use of eticlopride for in vivo, in vitro, and ex vivo examination of DA D2-like receptor densities and function. Finally, we discuss the use of eticlopride in several behavioral models predictive of antipsychotic activity, extrapyramidal side effects (EPS), and learning and memory. While eticlopride is not used clinically, it remains a viable research tool for understanding DA receptor function and behavior.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18801115      PMCID: PMC2753830          DOI: 10.1111/j.1755-5949.2008.00047.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  113 in total

Review 1.  The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum.

Authors:  D Joel; I Weiner
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not.

Authors:  S C Fowler; J R Liou
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

3.  Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride.

Authors:  M S Lidow; P S Goldman-Rakic; P Rakic; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

Review 4.  Atypical antipsychotics--recent findings and new perspectives.

Authors:  J A Lowe; T F Seeger; F J Vinick
Journal:  Med Res Rev       Date:  1988 Oct-Dec       Impact factor: 12.944

5.  Cloning and expression of a rat D2 dopamine receptor cDNA.

Authors:  J R Bunzow; H H Van Tol; D K Grandy; P Albert; J Salon; M Christie; C A Machida; K A Neve; O Civelli
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

6.  Withdrawal of remoxipride.

Authors:  N A Keks; G D Burrows
Journal:  Med J Aust       Date:  1994-05-02       Impact factor: 7.738

7.  Selective labelling of different dopamine receptors by a new agonist 3H-ligand: 3H-N-propylnorapomorphine.

Authors:  M Titeler; P Seeman
Journal:  Eur J Pharmacol       Date:  1979-06-15       Impact factor: 4.432

8.  Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation.

Authors:  F J Monsma; L C Mahan; L D McVittie; C R Gerfen; D R Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

9.  Sulpiride: assessment of a pharmacologically and chemically distinct neuroleptic.

Authors:  T D Rich
Journal:  Med Hypotheses       Date:  1984-05       Impact factor: 1.538

10.  Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride.

Authors:  C Köhler; A C Radesäter
Journal:  Neurosci Lett       Date:  1986-05-06       Impact factor: 3.046

View more
  17 in total

1.  Choice for response alternatives differing in reinforcement frequency in dopamine D2 receptor mutant and Swiss-Webster mice.

Authors:  Paul L Soto; Takato Hiranita; David K Grandy; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Quantitative unit classification of ventral tegmental area neurons in vivo.

Authors:  Wei Li; William M Doyon; John A Dani
Journal:  J Neurophysiol       Date:  2012-02-29       Impact factor: 2.714

3.  Central manipulation of dopamine receptors attenuates the orexigenic action of ghrelin.

Authors:  Amparo Romero-Picó; Marta G Novelle; Cintia Folgueira; Miguel López; Ruben Nogueiras; Carlos Diéguez
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

4.  Dopamine activity in the lateral anterior hypothalamus modulates AAS-induced aggression through D2 but not D5 receptors.

Authors:  Jared J Schwartzer; Richard H Melloni
Journal:  Behav Neurosci       Date:  2010-10       Impact factor: 1.912

5.  D2 antagonist during development decreases anxiety and infanticidal behavior in adult female prairie voles (Microtus ochrogaster).

Authors:  Caroline M Hostetler; Shanna L Harkey; Karen L Bales
Journal:  Behav Brain Res       Date:  2010-02-10       Impact factor: 3.332

6.  Optogenetic Stimulation of Midbrain Dopamine Neurons Produces Striatal Serotonin Release.

Authors:  Merel Dagher; Katie A Perrotta; Sara A Erwin; Ayaka Hachisuka; Rahul Iyer; Sotiris C Masmanidis; Hongyan Yang; Anne M Andrews
Journal:  ACS Chem Neurosci       Date:  2022-03-21       Impact factor: 5.780

7.  Neural Substrates of Dopamine D2 Receptor Modulated Executive Functions in the Monkey Prefrontal Cortex.

Authors:  M Victoria Puig; Earl K Miller
Journal:  Cereb Cortex       Date:  2014-05-09       Impact factor: 5.357

8.  Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration.

Authors:  Tracie A Paine; Samuel K Asinof; Geoffrey W Diehl; Anna Frackman; Joseph Leffler
Journal:  Behav Brain Res       Date:  2013-01-24       Impact factor: 3.332

9.  In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis.

Authors:  Melissa Mejia-Gutierrez; Bryan D Vásquez-Paz; Leonardo Fierro; Julio R Maza
Journal:  ACS Omega       Date:  2021-06-01

10.  Dopamine D(2) Antagonist-Induced Striatal Nur77 Expression Requires Activation of mGlu5 Receptors by Cortical Afferents.

Authors:  Jérôme Maheux; Michel St-Hilaire; David Voyer; Emanuele Tirotta; Emiliana Borrelli; Claude Rouillard; Pierre-Paul Rompré; Daniel Lévesque
Journal:  Front Pharmacol       Date:  2012-08-14       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.